Show simple item record

dc.contributor.authorGetting, SJ
dc.contributor.authorKaneva, M
dc.contributor.authorBhadresa, Y
dc.contributor.authorRenshaw, D
dc.contributor.authorLeoni, G
dc.contributor.authorPatel, HB
dc.contributor.authorKerrigan, MJP
dc.contributor.authorLocke, IC
dc.date.accessioned2021-03-25T11:49:00Z
dc.date.available2021-03-25T11:49:00Z
dc.date.issued2009-12-16
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/70865
dc.description.abstractArthritic pathologies are a major cause of morbidity within the western world, with rheumatoid arthritis affecting approximately 1% of adults. This review highlights the therapeutic potential of naturally occurring hormones and their peptides, in both arthritic models of disease and patients. The arthritides represent a group of closely related pathologies in which cytokines, joint destruction, and leukocytes play a causal role. Here we discuss the role of naturally occurring pro-opiomelanocortin (POMC)-derived melanocortin peptides (e.g., alpha melanocyte stimulating hormone [alpha-MSH]) and synthetic derivatives in these diseases. Melanocortins exhibit their biological efficacy by modulating proinflammatory cytokines and subsequent leukocyte extravasation. Their biological effects are mediated via seven transmembrane G-protein-coupled receptors, of which five have been cloned, identified, and termed MC1 to MC5. Adrenocorticotrophic hormone represents the parent molecule of the melanocortins; the first 13 amino acids of which (termed alpha-MSH) have been shown to be the most pharmacologically active region of the parent hormone. The melanocortin peptides have been shown to display potent anti-inflammatory effects in both animal models of disease and patients. The potential anti-inflammatory role for endogenous peptides in arthritic pathologies is in its infancy. The ability to inhibit leukocyte migration, release of cytokines, and induction of anti-inflammatory proteins appears to play an important role in affording protection in arthritic injury, and thus may lead to potential therapeutic targets.en_US
dc.format.extent1394 - 1414
dc.languageeng
dc.relation.ispartofScientificWorldJournal
dc.subjectAnimalsen_US
dc.subjectArthritisen_US
dc.subjectArthritis, Goutyen_US
dc.subjectArthritis, Rheumatoiden_US
dc.subjectHumansen_US
dc.subjectInflammationen_US
dc.subjectMelanocortinsen_US
dc.subjectOsteoarthritisen_US
dc.subjectReceptors, Melanocortinen_US
dc.subjectSignal Transductionen_US
dc.titleMelanocortin peptide therapy for the treatment of arthritic pathologies.en_US
dc.typeArticleen_US
dc.identifier.doi10.1100/tsw.2009.163
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/20024514en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume9en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record